CHF Solutions (NASDAQ: CHFS) is one of 46 public companies in the “Electromedical equipment” industry, but how does it weigh in compared to its competitors? We will compare CHF Solutions to related companies based on the strength of its valuation, institutional ownership, risk, analyst recommendations, profitability, earnings and dividends.
Insider & Institutional Ownership
3.9% of CHF Solutions shares are held by institutional investors. Comparatively, 40.7% of shares of all “Electromedical equipment” companies are held by institutional investors. 3.5% of CHF Solutions shares are held by company insiders. Comparatively, 20.2% of shares of all “Electromedical equipment” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
This table compares CHF Solutions and its competitors revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|CHF Solutions||$3.55 million||-$13.38 million||-0.09|
|CHF Solutions Competitors||$1.10 billion||$121.87 million||-38.68|
CHF Solutions’ competitors have higher revenue and earnings than CHF Solutions. CHF Solutions is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
This table compares CHF Solutions and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|CHF Solutions Competitors||-136.44%||32.35%||-12.78%|
Risk & Volatility
CHF Solutions has a beta of 2.25, suggesting that its stock price is 125% more volatile than the S&P 500. Comparatively, CHF Solutions’ competitors have a beta of 1.57, suggesting that their average stock price is 57% more volatile than the S&P 500.
This is a breakdown of current recommendations for CHF Solutions and its competitors, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|CHF Solutions Competitors||146||440||969||26||2.55|
CHF Solutions currently has a consensus target price of $65.00, suggesting a potential upside of 1,906.17%. As a group, “Electromedical equipment” companies have a potential upside of 7.59%. Given CHF Solutions’ stronger consensus rating and higher possible upside, equities research analysts clearly believe CHF Solutions is more favorable than its competitors.
CHF Solutions competitors beat CHF Solutions on 8 of the 12 factors compared.
CHF Solutions Company Profile
CHF Solutions, Inc., an early-stage medical device company, develops cardiac and coronary disease products primarily in the United States. It focused on commercializing the Aquadex FlexFlow system, which is indicated for temporary ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and extended ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization. The company was formerly known as Sunshine Heart, Inc. and changed its name to CHF Solutions, Inc. in May 2017. CHF Solutions, Inc. was founded in 1999 and is based in Eden Prairie, Minnesota.
Receive News & Ratings for CHF Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CHF Solutions and related companies with MarketBeat.com's FREE daily email newsletter.